New Study: Over-the-Counter Pain Relievers Speed Up Concussion Recovery

May 3, 2025

A major new study offers hope for athletes and others recovering from concussion: using over-the-counter (OTC) analgesics like acetaminophen and NSAIDs may significantly improve symptoms and reduce recovery time.

Researchers from the University of Washington Medical Center, working with NCAA athletes and military cadets, tracked over 1,600 young adults who experienced a concussion. They compared those who took OTC pain relievers after their injury to those who did not.

Faster Recovery: Athletes who used OTC analgesics reached 90% recovery about 7 days sooner than those who didn’t take any pain relievers.

Quicker Symptom Relief: Those taking OTC medications were cleared for unrestricted return to play faster and became asymptomatic sooner.

Lower Symptom Severity: Participants reported significantly less severe symptoms and headaches after taking OTC analgesics.

Timing Matters: Taking pain relievers within the first 24 hours after injury was especially effective, likely because early intervention targets the initial wave of inflammation following concussion.

Surprisingly, the study found no significant difference between the types of OTC pain relievers, acetaminophen and NSAIDs (like ibuprofen), both provided similar benefits for concussion recovery. This suggests that simply managing pain early on, regardless of the specific medication, can help speed up recovery.

Some of my colleagues feel that taking pain relievers or even migraine medications can delay the recovery. This study suggests that OTC pain relievers soon after a concussion may help reduce symptoms and speed recovery. Most headaches that occur after a concussion are migrainous in type and also respond to migraine drugs such as sumatriptan, rimegepant, and others. These headaches also respond to Botox injections, just like migraines.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe